I
Iambic Therapeutics IAM
$13.10
−11.73%
Nov 13
1W
1M
3M
Activities
Posts
No posts about IAM yet.
About Iambic Therapeutics, Inc. Common Stock
Iambic Therapeutics develops cancer drugs using AI and computational methods to design them. Its lead drug, IAM1363, is a pill for HER2 tumors in an early trial. It earns small fees from drug-discovery partners and relies on IPO money to fund its losses.